Lukas von Stülpnagel

Lukas von Stülpnagel

Auto-generated profile, based on publicly available information

Lukas von Stülpnagel

Medizinische Klinik und Poliklinik I, LMU University Hospital, LMU Medizin, Ludwig Maximilians Universität München, Munich, Germany

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2022 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
KRKonstantinos D. Rizas
Konstantinos D. Rizas
LFLuisa Freyer
Luisa Freyer
NSNikolay Sappler
Nikolay Sappler
LSLukas von Stülpnagel
Lukas von Stülpnagel
PSPeter Spielbichler
Peter Spielbichler
ABAxel Bauer
Axel Bauer

1 August 2019 in Heart Rhythm
Verified
Journal Article
Closed access
KRKonstantinos D. Rizas
Konstantinos D. Rizas
ADAngela J. Doller
Angela J. Doller
WHWolfgang Hamm
Wolfgang Hamm
NVNikolay Vdovin
Nikolay Vdovin
LSLukas von Stuelpnagel
Lukas von Stuelpnagel
ABAxel Bauer
Axel Bauer

8 March 2023 in Clinical Research in Cardiology
Verified
Journal Article
Open access
PDF file
JHJulia Hoffmann
Julia Hoffmann
SHSabine Hanß
Sabine Hanß
MKMonika Kraus
Monika Kraus
JSJens Schaller
Jens Schaller
CSChristian Schäfer
Christian Schäfer
MNMatthias Nauck
Matthias Nauck
The German Centre for Cardiovascular Research (DZHK) is one of the German Centres for Health Research and aims to conduct early and guideline-relevant studies to develop new therapies and diagnostics that impact the lives of people with cardiovascular disease. Therefore, DZHK members designed a collaboratively organised and integrated research platform connecting all sites and partners. The overarching objectives of the research platform are the standardisation of prospective data and biological sample collections among all studies and the development of a sustainable centrally standardised storage in compliance with general legal regulations and the FAIR principles. The main elements of the DZHK infrastructure are web-based and central units for data management, LIMS, IDMS, and transfer office, embedded in a framework consisting of the DZHK Use and Access Policy, and the Ethics and Data Protection Concept. This framework is characterised by a modular design allowing a high standardisation across all studies. For studies that require even tighter criteria additional quality levels are defined. In addition, the Public Open Data strategy is an important focus of DZHK. The DZHK operates as one legal entity holding all rights of data and biological sample usage, according to the DZHK Use and Access Policy. All DZHK studies collect a basic set of data and biosamples, accompanied by specific clinical and imaging data and biobanking. The DZHK infrastructure was constructed by scientists with the focus on the needs of scientists conducting clinical studies. Through this, the DZHK enables the interdisciplinary and multiple use of data and biological samples by scientists inside and outside the DZHK. So far, 27 DZHK studies recruited well over 11,200 participants suffering from major cardiovascular disorders such as myocardial infarction or heart failure. Currently, data and samples of five DZHK studies of the DZHK Heart Bank can be applied for.

8 March 2022 in Circulation
Verified
Journal Article
Closed access
PDF file
RBRune Boas
Rune Boas
NSNikolay Sappler
Nikolay Sappler
LSLukas von Stülpnagel
Lukas von Stülpnagel
MKMathias Klemm
Mathias Klemm
UDUlrik Dixen
Ulrik Dixen
KRKonstantinos D. Rizas
Konstantinos D. Rizas
Background: Identification of patients with nonischemic cardiomyopathy who may benefit from prophylactic implantation of a cardioverter-defibrillator. We hypothesized that periodic repolarization dynamics (PRD), a marker of repolarization instability associated with sympathetic activity, could be used to identify patients who will benefit from prophylactic implantable cardioverter defibrillator (ICD) implantation. Methods: We performed a post hoc analysis of DANISH (Danish ICD Study in Patients With Dilated Cardiomyopathy), in which patients with nonischemic cardiomyopathy, left ventricular ejection fraction (LVEF) ≤35%, and elevated NT-proBNP (N-terminal probrain natriuretic peptides) were randomized to ICD implantation or control group. Patients were included in the PRD substudy if they had a 24-hour Holter monitor recording at baseline with technically acceptable ECG signals during the night hours (00:00–06:00). PRD was assessed using wavelet analysis according to previously validated methods. The primary end point was all-cause mortality. Cox regression models were adjusted for age, sex, NT-proBNP, estimated glomerular filtration rate, LVEF, atrial fibrillation, ventricular pacing, diabetes, cardiac resynchronization therapy, and mean heart rate. We proposed PRD ≥10 deg 2 as an exploratory cut-off value for ICD implantation. Results: A total of 748 of the 1116 patients in DANISH qualified for the PRD substudy. During a mean follow-up period of 5.1±2.0 years, 82 of 385 patients died in the ICD group and 85 of 363 patients died in the control group ( P =0.40). In Cox regression analysis, PRD was independently associated with mortality (hazard ratio [HR], 1.28 [95% CI, 1.09–1.50] per SD increase; P =0.003). PRD was significantly associated with mortality in the control group (HR, 1.51 [95% CI, 1.25–1.81]; P <0.001) but not in the ICD group (HR, 1.04 [95% CI, 0.83–1.54]; P =0.71). There was a significant interaction between PRD and the effect of ICD implantation on mortality ( P =0.008), with patients with higher PRD having greater benefit in terms of mortality reduction. ICD implantation was associated with an absolute mortality reduction of 17.5% in the 280 patients with PRD ≥10 deg 2 (HR, 0.54 [95% CI, 0.34–0.84]; P =0.006; number needed to treat=6), but not in the 468 patients with PRD <10 deg 2 (HR, 1.17 [95% CI, 0.77–1.78]; P =0.46; P for interaction=0.01). Conclusions: Increased PRD identified patients with nonischemic cardiomyopathy in whom prophylactic ICD implantation led to significant mortality reduction.

6 August 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
ABAndreas Boehmer
Andreas Boehmer
TSTim Schubert
Tim Schubert
MRMoritz Rothe
Moritz Rothe
CKChristoph Keim
Christoph Keim
LWLilli Wiedenmann
Lilli Wiedenmann
JEJoachim R Ehrlich
Joachim R Ehrlich
Background: Heart failure with reduced ejection fraction is associated with potentially deleterious imbalance of the cardiac autonomic nervous system. Sacubitril/valsartan (angiotensin receptor‐neprilysin inhibitor [ARNI]) reduces cardiovascular mortality and hospitalization for heart failure with reduced ejection fraction. Whether ARNI affects the cardiac autonomic nervous system has not been studied. Methods and Results: This investigator‐initiated, prospective, single‐center cohort study compared heart rate (HR) variability, HR, deceleration capacity, and periodic repolarization dynamics as noninvasive measures of the cardiac autonomic nervous system before and after initiation of ARNI therapy. Patients underwent standardized 12‐lead Holter‐ECG, echocardiography and laboratory testing before and 3 months after start of therapy. End points were changes in HR variability (SD of normal‐to‐normal intervals, mean square of differences between consecutive R‐R intervals), HR, deceleration capacity, and periodic repolarization dynamics as well as ventricular function and NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide). Of 63 patients with heart failure with reduced ejection fraction enrolled, 48 (76.2%) patients were still on ARNI at follow‐up. SD of normal‐to‐normal intervals increased from 25 to 36 milliseconds ( P <0.001), mean square of differences between consecutive R‐R intervals increased from 12 to 19 milliseconds ( P <0.001), HR decreased from 73±9 bpm to 67±4 bpm, ( P <0.001), and deceleration capacity increased from 2.1 to 4.4 milliseconds ( P <0.001). A trend for periodic repolarization dynamics reduction was observed (5.6 deg 2 versus 4.7 deg 2 , P =0.09). Autonomic changes were accompanied by increased left ventricular ejection fraction (29±6% versus 40±8%, P <0.001) and reduced NT‐proBNP (3548 versus 685 ng/L, P <0.001). Correlation analysis showed a significant relationship between volume‐unloading (as evidenced by NT‐proBNP reduction) and autonomic improvement. Conclusions: Three months of ARNI therapy resulted in a significant increase in cardiac parasympathetic tone. The improvement in autonomic properties may be mediated by “volume unloading” and likely contributes to the beneficial effects of ARNI in heart failure with reduced ejection fraction. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT04587947.

29 August 2026 in Nature Medicine
Verified
Journal Article
Open access
PDF file
KRKonstantinos D. Rizas
Konstantinos D. Rizas
Konstantinos MourouzisKonstantinos Mourouzis
Konstantinos Mourouzis
DRDominik Rath
Dominik Rath
COChristoph B. Olivier
Christoph B. Olivier
LSLaura Elisa Villegas Sierra
Laura Elisa Villegas Sierra
SMSteffen Massberg
Steffen Massberg
The selection of the optimal antithrombotic regimen in patients with atrial fibrillation and acute coronary syndrome remains challenging. Previous trials have demonstrated that dual antithrombotic therapy (DAT), consisting of direct oral anticoagulants (DOACs) plus a P2Y12 inhibitor, reduces bleeding compared to a triple-therapy regimen using vitamin K antagonists. However, subsequent meta-analyses have suggested an increased risk of ischemic events with DAT, particularly within the first month of treatment. Clopidogrel has been the predominant P2Y12 inhibitor used across these studies, despite the risk of high on-treatment platelet reactivity when using this drug. In this study, we conducted an open-label, randomized controlled trial (EPIDAURUS) in patients with atrial fibrillation and acute coronary syndrome, designed to assess the efficacy and safety of a 1-month regimen of DOAC plus potent P2Y12 inhibitor (prasugrel or ticagrelor) compared to DOAC plus clopidogrel and in-hospital aspirin. The primary outcomes of the trial were an efficacy endpoint, recurrent ischemic events and safety endpoints, including death and major bleeding, which were evaluated 6 weeks after randomization using separate win−loss ratio analyses. The study was prematurely terminated after enrollment of 602 patients (154 female) of an expected 1,474 patients, owing to safety concerns raised by the Data and Safety Monitoring Board. Exploratory analyses of secondary safety endpoints, including bleeding type ≥2 and ≥3 according to the Bleeding Academic Research Consortium scale, revealed that, compared to clopidogrel and in-hospital aspirin, treatment with a potent P2Y12 inhibitor was associated with higher bleeding rates without a clear reduction in the risk of ischemic complications. These findings do not support the routine use of potent P2Y12 inhibitors in combination with DOACs in this patient population. ClinicalTrials.gov identifier: NCT04981041 .